Clinical Challenges: JAK Inhibitors for Atopic Dermatitis
Strong efficacy data for new class of agents in AD, but some apprehension over safety warnings
Source: medpagetoday.com
Page 2 - Lawrencef Eichenfield News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Lawrencef Eichenfield. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Lawrencef Eichenfield Today - Breaking & Trending Today
Study Finds Ruxolitinib Effective, Safe for Children With AD
There were no significant safety signals in the younger pediatric population, and 'no treatment-emergent adverse events suggestive of systemic JAK inhibition,' Dr Lawrence Eichenfield said.
Source: medscape.com
Crisaborole Effective for Long-Term Maintenance in Mild-to-Moderate Eczema
Longer median time of flare-free maintenance, greater number of flare-free days, and lower mean number of flares.
Source: empr.com
Crisaborole Effective for Long-Term Maintenance in Mild-to-Moderate Eczema
WEDNESDAY, June 28, 2023 (HealthDay News) -- Crisaborole is effective as a long-term maintenance therapy for pediatric and adult patients with mild-to-moderate atopic dermatitis (AD), according to a study published
Source: sanfordherald.com
Crisaborole Effective for Long-Term Maintenance in Mild-to-Moderate Eczema
WEDNESDAY, June 28, 2023 (HealthDay News) -- Crisaborole is effective as a long-term maintenance therapy for pediatric and adult patients with mild-to-moderate atopic dermatitis (AD), according to a study published
Source: kpvi.com